Evolent Health Inc (EVH) is Reiterated by FBR Capital to Outperform, Raises Price Target to $ 24

Evolent Health Inc (EVH) was Reiterated by FBR Capital to “Outperform” according to the research note released today. The brokerage firm has raised the Price Target to $ 24 from a previous price target of $16 . FBR Capital advised their investors in a research report released on Jul 13, 2016.

On the company’s financial health, Evolent Health Inc reported $-0.16 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 12, 2016. Analyst had a consensus of $-0.20. The company had revenue of $49.50 million for the quarter, compared to analysts expectations of $47.42 million. The company’s revenue was up 33.8% compared to the same quarter last year.

Evolent Health Inc closed down -0.38 points or -2.02% at $18.4 with 2,70,745 shares getting traded on Monday. Post opening the session at $18.93, the shares hit an intraday low of $18.26 and an intraday high of $18.99 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

In a different news, on Jun 10, 2015, Gary Piefer (Chief Medical Officer) purchased 2,000 shares at $17.00 per share price.

Evolent Health Inc. is engaged in the healthcare delivery and payment markets. The Company’s platform enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to value-based payment models. It provides an end-to-end technology-enabled services platform for providers to transition their organization in value-based payment models. It markets and sells services to providers throughout the United States. The Company works with its partners in two phases. In the transformation phase it works with its partners to develop a plan for their transition to a value-based care model. During the second portion of the transformation phase the Company works with its partner to implement the Blueprint. During the transformation phase the Company seeks to enter into long-term agreements with its partners. In the platform and operations phase the Company establishes a local market presence and embeds its resources alongside the Company’s partners.

Evolent Health Inc

Leave a Reply

Evolent Health Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Evolent Health Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.